The initial isolate is being developed as an anti-cancer therapeutic by virtual company Neotropix, Inc. under the name NTX-010. Phase I *Safety study of<unk>  in patients with solid tumors with neuroendocrine features. This study was published in 2011 and the data show that the virus was well tolerated by 30 patients and some signs of anti-tumour activity were observed. The data warranted further investigation of the virus in a phase II trial in small cell lung cancer. Phase II<unk>  after chemotherapy in treating patients with extensive-stage small cell lung cancer<unk>  and cyclophosphamide in young patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features
Senecavirus
Coronavirus 
Coronavirus
Orthohantavirus
Arbovirus
Pandoravirus
Andes orthohantavirus
Flavivirus